Researcher
Piet Ost
- Keywords:Radiotherapy, Prostate Cancer
- Disciplines:Cancer therapy, Palliative care and end-of-life care, Urology, Radiation therapy
Affiliations
- Department of Human Structure and Repair (Department)
Member
From1 Oct 2018 → Today - Dean's Office of the Faculty of Medicine and Health Sciences (Administrative office)
Member
From1 Jul 2012 → 30 Sep 2012 - Department of Radiation oncology and experimental cancer research (Department)
Member
From1 Nov 2008 → 30 Sep 2018
Projects
1 - 10 of 13
- Omics analysis in liquid biopsy samples of advanced tumoursFrom1 Nov 2023 → TodayFunding: BOF - doctoral mandates
- Digital pathology as a proxy for molecular profiling of prostate tumorsFrom1 Oct 2022 → TodayFunding: BOF - projects
- Detection of biomarkers to reduce radiation-induced toxicities and improve clinical outcomes, with emphasis on the role of unintended dose.From1 Sep 2022 → 31 Aug 2023Funding: Nonprofit institution or equivalents
- Study of the molecular mechanisms of metastasis in prostate cancer.From1 Oct 2021 → 31 Jan 2022Funding: BOF - doctoral mandates
- ProBio: an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker-driven trial in patients with metastatic castration-resistant prostate cancerFrom1 Feb 2020 → 31 Jan 2024Funding: Nonprofit institution or equivalents
- A data-driven integrative framework for the identification of cancer driver pathways and their mode of action.From1 Nov 2019 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
- CHEckpoint inhibition in combination with an immunoboost of External body adiotherapy in oligometastatic or oligoprogressive Solid tumors: CHEERS-trialFrom1 Jul 2018 → 30 Jun 2023Funding: Nonprofit institution or equivalents
- Effect and process evaluation of an intervention program on physical activity and sedentary behavior in castrate resistant prostate cancer patientsFrom1 Oct 2017 → 30 Sep 2022Funding: FWO fellowships
- PEACE V: a randomized phase III trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)From1 Jan 2017 → 31 Oct 2021Funding: BOF - Doctoral projects
- A randomized phase II trial for the Treatment of Oligorecurrent nodal prostate cancer: TOREN-trial.From1 Jan 2017 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 243
- Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy : real-world data from the E2-RADIatE OligoCare cohort(2024)
Authors: Renée Bultijnck, Mieke Van Hemelrijck, Valerie Fonteyne, Lorenzo Livi, Barbara Alicja Jereczek-Fossa, Hossein Hemmatazad, Michael Mayinger, Heike Peulen, Luc Verbeke, Sara Ramella, et al.
- Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer(2023)
Authors: Marija Pizurica, Maarten Larmuseau, Kim Van der Eecken, Louise de Schaetzen van Brienen, Francisco Carrillo-Perez, Simon Valentijn Isphording, Nicolaas Lumen, Jo Van Dorpe, Piet Ost, Sofie Verbeke, et al.
Pages: 2970 - 2984 - AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer(2023)
Authors: Jan Vanwelkenhuyzen, Eva Van Bos, Siska Van Bruwaene, Karl Lesage, Alex Maes, Sezgin Üstmert, Filip Lavent, Laurence Beels, Henrik Grönberg, Piet Ost, et al.
Pages: 63 - 66 - Experiences of men with prostate cancer participating in a clinical pathway with a supervised group-based exercise program to combat androgen deprivation-induced side effects : a qualitative focus group study(2023)
Authors: Renée Bultijnck, Elke Rammant, Karel Decaestecker, Valerie Fonteyne, Nicolaas Lumen, Piet Ost, Benedicte Deforche
- Dosimetric and hematologic implications of prostate-only versus whole pelvic radiotherapy : results of the multicentric phase 3 PROPER study(2023)
Authors: Valerie Fonteyne, Willeke Danckaert, Piet Ost, Charlien Berghen, Katrien Vandecasteele, Ben Vanneste, Kato Rans, Nick Liefhooghe, Steven Wallaert, Leen Paelinck
- Microbiome and metabolome dynamics during radiotherapy for prostate cancer(2023)
Authors: Willeke Danckaert, Mathieu Spaas, Nora Sundahl, Aurélie De Bruycker, Valerie Fonteyne, Ellen De Paepe, Carlos De Wagter, Lynn Vanhaecke, Piet Ost
- Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial(2023)
Authors: Mathieu Spaas, Nora Sundahl, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Fréderic Duprez, Yolande Lievens, Veerle Surmont, Lieve Brochez, Dries Reynders, et al.
Pages: 1205 - 1213 - WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer(2023)
Authors: Philip Sutera, Matthew P. Deek, Kim Van der Eecken, Amol C. Shetty, Jin Hee Chang, Theresa Hodges, Yang Song, Sofie Verbeke, Jo Van Dorpe, Valerie Fonteyne, et al.
Pages: 1095 - 1101 - Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors : a systematic review of the literature(2022)
Authors: Willeke Danckaert, Mathieu Spaas, Piet Ost
Pages: 64 - 69 - Adjuvant radiotherapy after radical cystectomy for patients with high-risk muscle-invasive bladder cancer : results of a multicentric phase II trial(2022)
Authors: P. Dirix, C. Berghen, M. Albersen, S. Junius, N. Liefhooghe, L. Noé, G. De Meerleer, Piet Ost, Daan De Maeseneer, Flor Verghote, et al.
Pages: 1238 - 1245